FDA approves BioSphere's embolic catheter:
This article was originally published in Clinica
Executive Summary
BioSphere Medical has gained US FDA approval to sell its EmboCath hydrophilic infusion catheter, which can be used in conjunction with the firm's microsphere technology. The EmboCath catheter will offer physicians a more targeted and controlled method for delivery of embolic material compared with standard angiographic catheters, said the Rockland, Massachusetts firm. The company also claims that EmboCath is a cost-effective alternative to currently available high-end micro-catheters, used commonly in embolotherapy procedures. BioSphere also plans to bring the product into Europe, pending CE-mark approval.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.